Free Trial

Insider Buying: TriSalus Life Sciences, Inc. (NASDAQ:TLSI) CEO Purchases 4,826 Shares of Stock

TriSalus Life Sciences logo with Medical background

TriSalus Life Sciences, Inc. (NASDAQ:TLSI - Get Free Report) CEO Mary T. Szela purchased 4,826 shares of the firm's stock in a transaction that occurred on Monday, January 27th. The stock was bought at an average price of $5.42 per share, for a total transaction of $26,156.92. Following the purchase, the chief executive officer now owns 429,503 shares in the company, valued at $2,327,906.26. The trade was a 1.14 % increase in their position. The purchase was disclosed in a document filed with the SEC, which is accessible through this link.

TriSalus Life Sciences Stock Performance

Shares of NASDAQ TLSI remained flat at $5.11 during mid-day trading on Friday. The company had a trading volume of 61,315 shares, compared to its average volume of 21,547. The firm has a market cap of $155.80 million, a price-to-earnings ratio of -2.05 and a beta of 0.51. The company has a 50 day moving average price of $4.60 and a 200-day moving average price of $4.75. TriSalus Life Sciences, Inc. has a 52 week low of $3.50 and a 52 week high of $10.42.

Analyst Upgrades and Downgrades

A number of brokerages have recently issued reports on TLSI. Cantor Fitzgerald initiated coverage on TriSalus Life Sciences in a report on Tuesday, December 17th. They set an "overweight" rating and a $10.00 price objective for the company. Northland Securities began coverage on TriSalus Life Sciences in a research note on Friday, October 25th. They issued an "outperform" rating and a $12.50 price target for the company. Roth Capital raised TriSalus Life Sciences to a "strong-buy" rating in a report on Monday, November 11th. Canaccord Genuity Group decreased their price target on shares of TriSalus Life Sciences from $12.00 to $11.00 and set a "buy" rating on the stock in a research note on Friday, November 15th. Finally, Roth Mkm reiterated a "buy" rating and issued a $11.00 price objective on shares of TriSalus Life Sciences in a research note on Friday, January 24th. Seven research analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat, the company has an average rating of "Buy" and an average target price of $11.79.

Get Our Latest Stock Analysis on TLSI

Hedge Funds Weigh In On TriSalus Life Sciences

Hedge funds have recently bought and sold shares of the company. Geode Capital Management LLC lifted its holdings in shares of TriSalus Life Sciences by 45.4% during the 3rd quarter. Geode Capital Management LLC now owns 200,427 shares of the company's stock worth $924,000 after acquiring an additional 62,542 shares during the period. MSD Partners L.P. bought a new stake in shares of TriSalus Life Sciences during the third quarter worth $184,000. Vestcor Inc acquired a new position in shares of TriSalus Life Sciences during the third quarter worth $108,000. Virtu Financial LLC bought a new position in shares of TriSalus Life Sciences in the 3rd quarter valued at $92,000. Finally, Walleye Capital LLC acquired a new stake in shares of TriSalus Life Sciences during the 3rd quarter valued at $66,000. 2.58% of the stock is owned by institutional investors.

TriSalus Life Sciences Company Profile

(Get Free Report)

TriSalus Life Sciences, Inc, a medical technology company, researches, develops, and sells drug delivery technologies and immune-oncology therapeutics for the treatment of liver and pancreatic cancer. The company offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial, for locally advanced pancreatic cancer.

See Also

Insider Buying and Selling by Quarter for TriSalus Life Sciences (NASDAQ:TLSI)

Should You Invest $1,000 in TriSalus Life Sciences Right Now?

Before you consider TriSalus Life Sciences, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and TriSalus Life Sciences wasn't on the list.

While TriSalus Life Sciences currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Unlock the Potential in Options Trading Cover

Options trading isn’t just for the Wall Street elite; it’s an accessible strategy for anyone armed with the proper knowledge. Think of options as a strategic toolkit, with each tool designed for a specific financial task. Get this report to learn how options trading can help you use the market’s volatility to your advantage.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

7 High-Growth Stocks Under $10
These Are the 3 Stocks Most Likely to SPLIT in 2025
NVIDIA Earnings: Will it Spark a Rally or Trigger a Sell-Off?

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines